152 related articles for article (PubMed ID: 20484616)
21. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
Nolin TD; Gastonguay MR; Bies RR; Matzke GR; Frye RF
Clin Pharmacol Ther; 2003 Dec; 74(6):555-68. PubMed ID: 14663458
[TBL] [Abstract][Full Text] [Related]
22. End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil.
Dahaba AA; Oettl K; von Klobucar F; Reibnegger G; List WF
Can J Anaesth; 2002 Apr; 49(4):369-74. PubMed ID: 11927475
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
24. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Schroeder PE; Hasinoff BB
Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
[TBL] [Abstract][Full Text] [Related]
25. Are dosing adjustments required for colchicine in the elderly compared with younger patients?
Wason S; Faulkner RD; Davis MW
Adv Ther; 2012 Jun; 29(6):551-61. PubMed ID: 22753019
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
27. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.
Kowalsky SF; Echols RM; Parker MA
Clin Pharm; 1985; 4(2):177-81. PubMed ID: 3987216
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function.
Phillips M; Smith W; Balan G; Ward S
J Clin Pharmacol; 2008 Mar; 48(3):279-84. PubMed ID: 18192538
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.
Türck D; Weber W; Sigmund R; Budde K; Neumayer HH; Fritsche L; Rominger KL; Feifel U; Slowinski T
J Clin Pharmacol; 2004 Feb; 44(2):163-72. PubMed ID: 14747425
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries.
Lovering AM; Le Floch R; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Vinsonneau C
J Antimicrob Chemother; 2009 Mar; 63(3):553-9. PubMed ID: 19153078
[TBL] [Abstract][Full Text] [Related]
32. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment.
Jungheinrich C; Scharpf R; Wargenau M; Bepperling F; Baron JF
Anesth Analg; 2002 Sep; 95(3):544-51, table of contents. PubMed ID: 12198032
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis.
Mistry GC; Majumdar AK; Swan S; Sica D; Fisher A; Xu Y; Hesney M; Xi L; Wagner JA; Deutsch PJ
J Clin Pharmacol; 2006 Oct; 46(10):1128-38. PubMed ID: 16988201
[TBL] [Abstract][Full Text] [Related]
34. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.
Courtney R; Sansone A; Smith W; Marbury T; Statkevich P; Martinho M; Laughlin M; Swan S
J Clin Pharmacol; 2005 Feb; 45(2):185-92. PubMed ID: 15647411
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
Noveck RJ; Preston RA; Swan SK
Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
[TBL] [Abstract][Full Text] [Related]
36. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
Cass LM; Efthymiopoulos C; Marsh J; Bye A
Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
[TBL] [Abstract][Full Text] [Related]
37. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
Johnson FK; Mudd PN; DiMino T; Vosk J; Sitaraman S; Boudes P; France N; Barlow C
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):256-61. PubMed ID: 27136905
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Tajima N; Ishizuka H; Naganuma H
Chemotherapy; 2006; 52(5):245-53. PubMed ID: 16864999
[TBL] [Abstract][Full Text] [Related]
39. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.
Dowell JA; Stogniew M; Krause D; Damle B
J Clin Pharmacol; 2007 Apr; 47(4):461-70. PubMed ID: 17389555
[TBL] [Abstract][Full Text] [Related]
40. Single dose pharmacokinetics of alpha-dihydroergocryptine in patients with moderate to severe renal insufficiency.
de Mey C; Sułowicz W; Stompór T; Ezan E; Retzow A; Althaus M
Arzneimittelforschung; 2003; 53(11):769-73. PubMed ID: 14677372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
